L'essentiel sur la grippe

6 novembre 2013

Dans cet article

Auteurs, liens et références

Rédacteur en chef

Dr Burke A Cunha, MD

State University of New York School of Medicine at Stony Brook; Winthrop-University Hospital

Liens d'intérêts financiers : aucun

Autres collaborateurs

Nicholas John Bennett

Connecticut Children's Medical Center - pas de conflit d'intérêt à déclarer.

Dr Ethan E Bodle

Kaiser Permanente East Bay Medical Center - pas de conflit d'intérêt à déclarer.

Dr Joseph Domachowske

State University of New York Upstate Medical University - pas de conflit d'intérêt à déclarer.

Dr Jon Mark Hirshon

University of Maryland School of Medicine - pas de conflit d'intérêt à déclarer.

Dr Edmond A Hooker II

University of Cincinnati College of Medicine - pas de conflit d'intérêt à déclarer.

Dr Joseph F John Jr

Medical  University of South Carolina College of Medicine; Ralph H  Johnson  Veterans Affairs Medical Center - pas de conflit d'intérêt à  déclarer.

Dr Ruth Lawrence

UC Davis Health System - pas de conflit d'intérêt à déclarer.

Dr Klaus-Dieter Lessnau

New York University School of Medicine; Lenox Hill Hospital - pas de conflit d'intérêt à déclarer.

Dr Frederick Burton Rose

State University of New York Upstate Medical University

Dr Charles V Sanders

Louisiana  State University School of Medicine at New Orleans; Charity  Hospital  and Medical Center of Louisiana at New Orleans - pas de conflit   d'intérêt à déclarer.

Francisco Talavera

University of Nebraska Medical Center College of Pharmacy

Liens d'intérêts financiers : Salarié Medscape

Dr David Yew

University  of Hawaii, John A Burns School of Medicine; Hawaii Life  Flight, AirMed  International ? pas de conflit d'intérêt à déclarer.

RÉFÉRENCES
  1. Centers   for Disease Control and Prevention. Key Facts About  Seasonal  Influenza (Flu).  Centers for Disease Control and Prevention. http://www.cdc.gov/flu/keyfacts.htm.

  2. Interim adjusted estimates of seasonal  influenza vaccine effectiveness - United States, February 2013. MMWR Morb  Mortal Wkly Rep. Feb 22 2013;62(7):119-23.

  3. Brown T. ACIP OKs 2014 adult immunization  schedule with changes. Medscape Medical News [serial online]. October  23, 2013; http://www.medscape.com/viewarticle/813119.

  4. Gu  Y,  Komiya N, Kamiya H, Yasui Y, Taniguchi K, Okabe N. Pandemic  (H1N1)  2009  transmission during presymptomatic phase, Japan. Emerg  Infect Dis. Sep 2011;17(9):1737-9.

  5. Guharoy R, Gilroy SA, Noviasky JA, Ference J.  West Nile virus infection. Am J Health Syst Pharm. Jun 15 2004;61(12):1235-41.

  6. Jefferson  T, Di Pietrantonj C, Rivetti A,  Bawazeer GA, Al-Ansary  LA, Ferroni E.  Vaccines for preventing influenza in  healthy adults. Cochrane Database Syst Rev. Jul 7 2010;CD001269.

  7. Brooks M.  FDA Okays 4-Strain Seasonal Influenza Vaccine. Medscape Medical News. December  17, 2012. http://www.medscape.com/viewarticle/776271?src=nl_newsalert.

  8. FDA  approves first quadrivalent vaccine to prevent seasonal influenza. US Food  & Drug Administration, February 29, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294057.htm.

  9. FDA  Approves First U.S. Vaccine for Humans Against the Avian Influenza Virus H5N1.  Center for Disease Control and Prevention. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108892.htm.

  10. Lee  VJ,  Yap J, Cook AR, Chen MI, Tay JK, Barr I, et al.  Effectiveness of  public health  measures in mitigating pandemic  influenza spread: a  prospective  sero-epidemiological cohort study. J  Infect Dis. Nov 1   2010;202(9):1319-26.

  11. Kilbourne  ED. Influenza pandemics of the 20th century. Emerg Infect Dis. Jan  2006;12(1):9-14.

  12. Seasonal   Influenza (Flu): Guidance for Clinicians on the Use of  RT-PCR and  Other  Molecular Assays for Diagnosis of Influenza Virus  Infection.  Centers for Disease  Control and Prevention. http://www.cdc.gov/flu/professionals/diagnosis/molecular-assays.htm.

  13. Gubareva  LV, Kaiser L, Hayden FG. Influenza virus neuraminidase  inhibitors. Lancet. Mar 4 2000;355(9206):827-35.

  14. Drake JW. Rates of spontaneous mutation among  RNA viruses. Proc Natl Acad Sci U S A. May 1 1993;90(9):4171-5.

  15. Avian  influenza ("bird flu"): fact sheet. World Health Organization. http://www.who.int/mediacentre/factsheets/avian_influenza/en/print.html.

  16. Bell  DM,  World Health Organization Writing Group.  Nonpharmaceutical  interventions for  pandemic influenza, international  measures. Emerg  Infect  Dis. Jan 2006;12(1):81-7.7.

  17. Auewarakul P, Suptawiwat O,   Kongchanagul A, Sangma C, Suzuki Y,  Ungchusak K, et al. An avian  influenza H5N1 virus that binds to a   human-type receptor. J Virol.  Sep 2007;81(18):9950-5.

  18. World   Health Organization. Cumulative number of confirmed human  cases of  avian  influenza A/(H5N1) reported to WHO. World Health  Organization. http://www.who.int/influenza/human_animal_interface/EN_GIP_20120810CumulativeNumberH5N1cases.pdf.

  19. Matsuzaki  Y, Abiko C, Mizuta K,  Sugawara K, Takashita E, Muraki  Y, et al. A  nationwide epidemic of influenza C virus infection in Japan  in 2004. J Clin Microbiol. Mar 2007;45(3):783-8.

  20. Update:  influenza activity - United States, 2011-12 season and composition of the  2012-13 influenza vaccine. MMWR Morb Mortal Wkly Rep. Jun 8 2012;61(22):414-20.

  21. Influenza (Seasonal) World Health Organization. http://www.who.int/mediacentre/factsheets/fs211/en.

  22. 2012-2013 Influenza Season Week 9 ending March  2, 2013. Centers for Disease Control and Prevention. http://www.cdc.gov/flu/weekly/.

  23. Centers  for Disease Control and Prevention. Seasonal Influenza: 2009-2010 Influenza  (Flu) Season. http://www.cdc.gov/flu/about/season/current-season.htm.

  24. Centers for Disease Control and Prevention.  Avian Influenza A Virus Infections in Humans. http://www.cdc.gov/flu/avianflu/avian-in-humans.htm.

  25. Wang et  al. Seroevidence for H5N1 infections in humans: a meta-analysis. Science. Mar 23 2012;335(6075):1463.

  26. Steininger  C, Popow-Kraupp T, Laferl H, Seiser  A, Gödl I,  Djamshidian S, et al.  Acute encephalopathy associated with influenza  A  virus infection. Clin Infect Dis. Mar 1 2003;36(5):567-74.

  27. Chertow  DS, Memoli MJ. Bacterial coinfection in influenza: a grand rounds review. JAMA. Jan 16 2013;309(3):275-82.

  28. Tasher  D, Stein M, Simões EA, Shohat T,  Bromberg M, Somekh E.  Invasive  bacterial infections in relation to influenza  outbreaks,  2006-2010.  Clin Infect Dis. Dec 2011;53(12):1199-207.

  29. Kumar K,  Guirgis M,  Zieroth S, Lo E, Menkis AH, Arora RC, et al.  Influenza myocarditis  and  myositis: case presentation and review of the  literature. Can J Cardiol. Jul-Aug 2011;27(4):514-22.

  30. Apisarnthanarak   A, Erb S, Stephenson I, Katz JM, Chittaganpitch  M, Sangkitporn S, et  al.  Seroprevalence of anti-H5 antibody among Thai  health care workers  after  exposure to avian influenza (H5N1) in a  tertiary care center. Clin Infect Dis. Jan 15 2005;40(2):e16-8.

  31. Interim   Guidance for Laboratory Testing of Persons with Suspected  Infection  with Highly  Pathogenic Avian Influenza A (H5N1) Virus in the  United  States. Center for  Disease Control and Prevention. http://www.cdc.gov/flu/avianflu/guidance-labtesting.htm.

  32. Clinical management of human infection with  avian influenza A (H5N1) virus. World Health Organization. http://www.who.int/influenza/resources/documents/ClinicalManagement07.pdf.

  33. World  Health Organization. H5N1 avian influenza: Timeline of major events. World  Health Organization. http://www.who.int/csr/disease/avian_influenza/Timeline_2007_03_20.pdf.

  34. U.S. Food  and Drug Administration. Performance and Cautions in Using Rapid Influenza  Virus Diagnostic Tests. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/TipsandArticlesonDeviceSafety/ucm109432.htm%20.

  35. Chartrand C, Leeflang MM, Minion J, Brewer T,  Pai M. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann  Intern Med. Apr 3 2012;156(7):500-11.

  36. Landry ML. Diagnostic tests for influenza  infection. Curr Opin Pediatr. Feb 2011;23(1):91-7.

  37. Haran  JP, Buglione-Corbett R, Lu S. Cytokine  markers as  predictors of type  of respiratory infection in patients during the   influenza season. Am J Emerg Med. May 2013;31(5):816-21.

  38. Oner AF,  Bay A, Arslan S, Akdeniz H, Sahin HA, Cesur Y, et al. Avian influenza A (H5N1)  infection in eastern Turkey in 2006. N Engl J Med. Nov 23 2006;355(21):2179-85..

  39. FDA Clears  Rapid Test for Avian Influenza A Virus in Humans. Center for Disease Control  and Prevention. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149557.htm.

  40. Beigel JH, Farrar J, Han AM,  Hayden FG, Hyer R, de Jong MD, et al. Avian influenza A (H5N1) infection in  humans. N Engl J Med. Sep 29 2005;353(13):1374-85.

  41. Chotpitayasunondh  T, Ungchusak K,  Hanshaoworakul W, Chunsuthiwat  S, Sawanpanyalert P,  Kijphati R, et al. Human disease from influenza A  (H5N1),  Thailand,  2004. Emerg Infect Dis. Feb  2005;11(2):201-9.

  42. Brown T.  CDC Releases New H7N9 Testing Recommendations. Medscape [serial online]. http://www.medscape.com/viewarticle/805620.

  43. CDC. Human  Infections with Avian Influenza A (H7N9) Viruses. Centers for Disease Control  and Prevention (CDC). http://www.bt.cdc.gov/HAN/han00347.asp.

  44. Preventing Seasonal Flu With Vaccination.  Centers for Disease Control and Prevention. http://www.cdc.gov/flu/protect/vaccine/.

  45. Centers  for Disease Control and Prevention.  Antiviral Agents for  the  Treatment and Chemoprophylaxis of Influenza.  Recommendations of the   Advisory Committee on Immunization Practices (ACIP). http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6001a1.htm?s_cid=rr6001a1_e.

  46. Barclay L. Influenza: Vaccinate Kids as Soon as  Possible, AAP Says. Medscape Medical News [serial online]. Sep 2 2013; http://www.medscape.com/viewarticle/810316.

  47. American Academy of Pediatrics. Recommendations  for Prevention and Control of Influenza in Children, 2013?2014. Pediatrics [serial online]. Sep 2 2013; http://pediatrics.aappublications.org/content/early/2013/08/28/peds.2013-2377.abstract.

  48. Selecting  the Viruses in the Seasonal Influenza (Flu) Vaccine. Centers for Disease  Control and Prevention. http://www.cdc.gov/flu/professionals/vaccination/virusqa.htm#virus-selection.

  49. Carr  S, Allison KJ, Van De Velde  LA, Zhang K, English EY, Iverson  A, et  al. Safety and immunogenicity of live attenuated and inactivated   influenza  vaccines in children with cancer. J Infect Dis. Nov    2011;204(10):1475-82.

  50. FDA approves first seasonal influenza  vaccine  manufactured using  cell culture technology. US Food & Drug  Administration.  November  20, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm.

  51. Lowes R.  FDA Okays Novel Flu Vaccine Made Without Eggs, Viruses. Medscape Medical News.  Jan 16 2013. http://www.medscape.com/viewarticle/777773.

  52. FDA. FDA  Approves New Seasonal Influenza Vaccine Made Using Novel Technology. US Food  and Drug Administration. Jan 16 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.htm.

  53. CDC advisory committee recommends an influenza  vaccine option for persons with egg allergy. http://www.cdc.gov/media/releases/2013/a0620-FluBlok.html.

  54. Maternal  and Infant Outcomes Among Severely Ill  Pregnant and  Postpartum Women  with 2009 Pandemic Influenza A (H1N1) --- United   States, April  2009--August 2010. MMWR Morb Mortal Wkly Rep. Sep 9   2011;60:1193-6.

  55. Benowitz  I, Esposito DB, Gracey KD, Shapiro ED,  Vázquez M.  Influenza vaccine  given to pregnant women reduces hospitalization  due  to influenza in  their infants. Clin Infect Dis. Dec 15  2010;51(12):1355-61.

  56. [Best   Evidence] Falsey AR, Treanor JJ, Tornieporth N, Capellan J,  Gorse GJ.   Randomized, double-blind controlled phase 3 trial comparing  the  immunogenicity  of high-dose and standard-dose influenza vaccine in   adults 65 years of age and  older. J Infect Dis. Jul 15   2009;200(2):172-80.

  57. Hung IF,  Leung AY, Chu DW, Leung D, Cheung  T, Chan CK, et al.  Prevention of acute  myocardial infarction and  stroke among elderly  persons by dual pneumococcal and  influenza  vaccination: a prospective  cohort study. Clin  Infect Dis. Nov 1  2010;51(9):1007-16.

  58. Christenson  B, Pauksen K, Sylvan SP. Effect  of influenza and  pneumococcal vaccines in  elderly persons in years of  low influenza  activity. Virol  J. Apr 28 2008;5:52.

  59. [Best   Evidence] Woods JA, Keylock KT, Lowder T, Vieira VJ,  Zelkovich W,  Dumich S, et  al. Cardiovascular exercise training extends  influenza  vaccine seroprotection  in sedentary older adults: the immune  function  intervention trial. J Am Geriatr Soc. Dec 2009;57(12):2183-91.

  60. Alsharifi  M, Furuya Y, Bowden TR,  et al. Intranasal flu vaccine   protective  against seasonal and H5N1 avian influenza infections. PLoS  One.  2009;4(4):e5336. doi: 10.1371/journal.pone.0005336. Epub 2009  Apr  29.

  61. MacMahon  KL, Delaney LJ, Kullman G, Gibbins JD,  Decker J, Kiefer  MJ.  Protecting poultry workers from exposure to avian  influenza  viruses. Public Health Rep. May-Jun 2008;123(3):316-22.

  62. Gray  GC,  Baker WS. The importance of including swine and poultry  workers  in influenza  vaccination programs. Clin Pharmacol Ther. 2007    Dec;82(6):638-41.

  63. H5N1  Influenza Virus Vaccine Questions and Answers. US Food and Drug Administration. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm080753.htm.

  64. Belshe  RB,  Frey SE, Graham I, Mulligan MJ, Edupuganti S, Jackson  LA, et al.  Safety and  immunogenicity of influenza A H5 subunit  vaccines: effect  of vaccine schedule  and antigenic variant. J Infect Dis. Mar 1 2011;203(5):666-73.

  65. Availability  of a new recombinant H5N1 vaccine virus. World Health Organization. http://www.who.int/influenza/vaccines/virus/h5n1virus09march/en/index.html.

  66. Gensheimer  KF, Meltzer MI, Postema AS, Strikas RA. Influenza pandemic preparedness. Emerg  Infect Dis. Dec 2003;9(12):1645-8.

  67. Centers  for Disease Control and Prevention.  Seasonal Influenza  (Flu):  Preventing the Flu: Good Health Habits Can Help Stop  Germs. http://www.cdc.gov/flu/protect/habits.htm..

  68. Adisasmito   W, Chan PK, Lee N, Oner AF, Gasimov V, Aghayev F, et  al.  Effectiveness of  antiviral treatment in human influenza A(H5N1)   infections: analysis of a Global  Patient Registry. J Infect Dis. Oct 15    2010;202(8):1154-60.

  69. Muthuri  SG, Myles PR, Venkatesan S,  Leonardi-Bee J,  Nguyen-Van-Tam JS. Impact of  neuraminidase inhibitor  treatment on  outcomes of public health importance  during the 2009-2010  influenza  A(H1N1) pandemic: a systematic review and  meta-analysis in  hospitalized  patients. J Infect Dis. Feb 15 2013;207(4):553-63.

  70. Lam  J, Nikhanj J, Ngab T, et al. Severe Cases of Pandemic H1N1  Pneumonia  and  Respiratory Failure Requiring Intensive Care. J Intensive   Care  Med. 5;26:318-25.

  71. Centers  for Disease Control and Prevention. Seasonal Influenza (Flu): Antiviral Drugs. http://www.cdc.gov/flu/professionals/antivirals/index.htm.

  72. Hayden  FG,  Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et  al. Use of  the selective  oral neuraminidase inhibitor oseltamivir to  prevent  influenza. N Engl J Med. Oct 28 1999;341(18):1336-43.

  73. Aoki FY,   Macleod MD, Paggiaro P, et al. Early administration of  oral oseltamivir  increases  the benefits of influenza treatment. J  Antimicrob   Chemother. 2003 Jan;51(1):123-9.

  74. Hill G,  Cihlar T, Oo C, Ho ES,  Prior K, Wiltshire H, et al. The  anti-influenza drug  oseltamivir  exhibits low potential to induce  pharmacokinetic drug interactions  via  renal secretion-correlation of in  vivo and in vitro studies. Drug  Metab Dispos. Jan 2002;30(1):13-9.

  75. Hayden FG,  Treanor JJ, Fritz  RS, Lobo M, Betts RF, Miller M, et  al. Use of the oral  neuraminidase  inhibitor oseltamivir in experimental  human influenza: randomized   controlled trials for prevention and  treatment. JAMA. Oct  6  1999;282(13):1240-6.

  76. Treanor  JJ, Hayden FG, Vrooman PS,  Barbarash R, Bettis R, Riff D,  et al. Efficacy and  safety of the oral  neuraminidase inhibitor  oseltamivir in treating acute influenza:  a  randomized controlled trial.  US Oral Neuraminidase Study  Group. JAMA.  Feb 23 2000;283(8):1016-24.

  77. Heinonen S, Silvennoinen H,   Lehtinen P, Vainionpää R, Vahlberg T,  Ziegler T, et al. Early  oseltamivir treatment of influenza in  children  1-3 years of age: a  randomized controlled trial. Clin  Infect Dis. Oct  15  2010;51(8):887-94.

  78. Jefferson T, Jones MA, Doshi P,  Del Mar CB,  Heneghan CJ, Hama R,  et al. Neuraminidase inhibitors for preventing and  treating influenza in   healthy adults and children. Cochrane Database Syst  Rev. Jan 18 2012;1:CD008965.

  79. Hayden  FG, Gubareva LV, Monto AS, Klein TC,  Elliot MJ, Hammond  JM, et al.  Inhaled zanamivir for the prevention of influenza  in  families.  Zanamivir Family Study Group. N Engl J Med. Nov 2   2000;343(18):1282-9.

  80. Randomised   trial of efficacy and safety of inhaled zanamivir in  treatment of  influenza A  and B virus infections. The MIST (Management  of Influenza  in the Southern  Hemisphere Trialists) Study Group. Lancet.  Dec 12   1998;352(9144):1877-81.

  81. Chamni S, De-Eknamkul W. Recent progress and  challenges in the discovery of new neuraminidase inhibitors. Expert Opin  Ther Pat. Apr 2013;23(4):409-23.

  82. Watanabe  A, Chang SC, Kim MJ, Chu DW, Ohashi Y.  Long-acting  neuraminidase  inhibitor laninamivir octanoate versus oseltamivir  for  treatment of  influenza: A double-blind, randomized, noninferiority  clinical  trial.  Clin Infect Dis. Nov 15 2010;51(10):1167-75.

  83. Kohno S, Kida H,  Mizuguchi M, Shimada J.  Efficacy and safety of  intravenous peramivir  for treatment of seasonal influenza  virus  infection. Antimicrob Agents  Chemother. Nov 2010;54(11):4568-74.

 

Commenter

3090D553-9492-4563-8681-AD288FA52ACE
Les commentaires peuvent être sujets à modération. Veuillez consulter les Conditions d'utilisation du forum.

Traitement....